
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion Inc is experiencing significant commercial momentum, evidenced by new agreements with major healthcare providers such as the Spine Institute of Louisiana, Medical Imaging Center of Southern California, and affiliates of RadNet, indicating a broadening market presence. The company reported a remarkable 132% year-over-year growth in scans for the second quarter, coupled with a 76% year-over-year increase in revenues, which reinforces the potential for continued growth as Nociscan adoption accelerates. These factors suggest a strengthening business model and increasing demand for its proprietary services, positioning Aclarion favorably within the healthcare technology sector.
Bears say
Aclarion Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to slower-than-expected traction with payers, which may hinder revenue growth from its Nociscan product. The company is adjusting its fiscal year 2025 earnings per share estimate downward to $(15.08), reflecting an anticipated increase in marketing and administrative expenses that could further strain profitability. Additionally, various risks, including balance sheet and liquidity issues, regulatory hurdles, and competitiveness in the healthcare market, present ongoing threats to the company's financial stability and long-term viability.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares